Clinical trial
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not…
NCT00003635 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00003635 |
|---|---|
| Title | 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents |
| Official title | A Multicenter Study to Assess the Efficacy of 506U78 in Patients With Chronic Lymphocytic Leukemia Who Are Refractory to Fludarabine and Alkylator Therapy |
| Lead sponsor | GlaxoSmithKline, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | nelarabine |
| Start date | Jan 1, 1999 |
| Completion | Mar 1, 2004 |
| First posted | Mar 31, 2004 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: